Fapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline
Fapon Biopharma is presenting its core technology platforms and pipeline at the AACR Annual Meeting 2026, showcasing novel cytokine-based fusion proteins and T-cell engagers for cancer and autoimmune diseases. The company is advancing several programs, including FP008 and FP012, with Phase I readout and IND-enabling studies planned for 2026.
Fapon Biopharma is presenting its technology platforms and pipeline at the AACR Annual Meeting 2026. The company's IL-10 biased functional engineering and antibody fusion platform underpins novel cytokine-based fusion proteins for immune modulation. FP008, a PD1 x IL10M fusion protein, is a potential next-generation backbone for cancer immunotherapy, with Phase I readout anticipated in 2026. Fapon Biopharma is also advancing FP012, a TL1A x IL10MM fusion protein for inflammatory bowel disease. The company's VHH human-monkey cross-binding T-cell engager platform is represented in its CD3/TCR VHHs, including FPE024 and FPE021, expected to enter IND-enabling studies in 2026. Fapon Biopharma is seeking strategic partners for co-development and licensing.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.